Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...
It will be marketed as Alyftrek. Vertex also won expanded approval for Trikafta, which was first approved in 2019. Trikafta has become Vertex’s (Nasdaq: VRTX) blockbuster CF drug, helping drive ...
Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...